Alantra advises Ypsomed on the sale of its pen needle and blood glucose monitoring systems business to Italy-based MTD
SECTORHealthcare
ServiceM&A
Zurich – Alantra has acted as the exclusive financial advisor to Ypsomed, a leading developer and manufacturer of injection and infusion systems for self-medication, on the sale of its pen needle and blood glucose monitoring (BGM) systems business to Italy-based Medical Technology and Devices (MTD), a portfolio company of Investindustrial and QuattroR.
Ypsomed is a leading developer and manufacturer of injection and infusion systems for self-medication. Renowned for its innovation and technological prowess, Ypsomed is the preferred partner of pharmaceutical and biotech companies for pens, autoinjectors, and pump systems used in administering liquid medications. Ypsomed markets its diabetes care product portfolios under the umbrella brand mylife Diabetescare directly to patients, pharmacies, and hospitals, and operates under Ypsomed Delivery Systems in business-to-business operations with pharmaceutical companies. Headquartered in Burgdorf, Switzerland, the company boasts a global network of production facilities, subsidiaries, and distribution partners, with over 2,200 employees worldwide.
MTD is a leading medical technology group that designs, manufactures, and provides a comprehensive range of medical devices for self-care and professional use worldwide. Established in 2018 through the merger of Pikdare and HTL Strefa, MTD brings together long-term and unique expertise in the development of medical sharps, home-use electromedical devices, and pharmaceutical self-care solutions. Its products are distributed in over 100 countries worldwide.
Alantra successfully conducted a tailored sales process and supported in the carve-out preparation, provided strategic, tactical, and valuation advice, managed the project during the due diligence process, and played an important role in negotiating the transaction.
Martin Menzi, Managing Director at Alantra, said: “This transaction marks another key step for Ypsomed in executing its growth strategy. Following our advisory role in the disposal of DiaExpert in 2022, we are happy to have found a new home for the pen needle and BGM product business as well.”
The transaction is subject to usual approvals and is expected to close in the coming months.
